Publications by authors named "M Llamas-Velasco"
Background And Objective: Risankizumab - a humanized monoclonal antibody that targets the p19 subunit of IL-23 - has been recently approved to treat moderate-to-severe plaque psoriasis. Real-world data based on a representative pool of patients are currently lacking.
Objective: To assess the mid- and long-term safety and efficacy profile of risankizumab in patients with moderate-to-severe psoriasis in the routine clinical practice.
Article Synopsis
- - In 2017, the Spanish Academy of Dermatology created the Minimal Disease Activity (MDA) criteria to assess psoriasis severity, and this study aimed to evaluate its nationwide application across Spain.
- - The study included 830 psoriasis patients, showing that over 59% did not meet MDA criteria, with significant variances observed based on region, sex, age, and treatment type.
- - Results indicated that patients using biological therapies had better MDA compliance compared to those on other treatments, suggesting a need for more effective management of psoriasis across different demographics.
Article Synopsis
- In a study on palmoplantar psoriasis, risankizumab (RZB) was evaluated against a placebo (PBO) for 16 weeks, followed by an extension to week 52.
- The results showed that RZB significantly outperformed PBO in achieving clear or nearly clear skin, with various response measures showing marked improvement at week 16.
- RZB was found to be well-tolerated, with no new safety issues arising throughout the study, though it was noted that there was no comparison with other biologic treatments.
Detecting the association of genetic variants to the response of biological therapy represents an important advance in developing a personalized therapy. The aim of this work was to study the association of polymorphisms with an optimal response to tildrakizumab in patients with psoriasis in a real-life clinical practice. Ninety patients with plaque psoriasis recruited from-Spanish hospitals receiving tildrakizumab for at least 24 weeks were genotyped for 180 polymorphisms.
View Article and Find Full Text PDF